 NEW YORK , July 21, 2022 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX the Company, a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26 th at 4:30pm ET and will be hosted by the Companys Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. 